Vident Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.28M | Buy |
3,925
+1,258
| +47% | +$410K | 0.01% | 644 |
|
|
2025
Q1 | $720K | Buy |
2,667
+1,340
| +101% | +$362K | 0.01% | 849 |
|
|
2024
Q4 | $312K | Buy |
1,327
+232
| +21% | +$54.6K | 0.01% | 1156 |
|
|
2024
Q3 | $301K | Sell |
1,095
-654
| -37% | -$180K | 0.01% | 1132 |
|
|
2024
Q2 | $425K | Buy |
1,749
+188
| +12% | +$45.7K | 0.01% | 980 |
|
|
2024
Q1 | $233K | Sell |
1,561
-308
| -16% | -$46K | ﹤0.01% | 1147 |
|
|
2023
Q4 | $358K | Buy |
1,869
+124
| +7% | +$23.7K | 0.01% | 917 |
|
|
2023
Q3 | $309K | Buy |
+1,745
| New | +$309K | 0.01% | 884 |
|